Navigation Links
Physician to Implant the CATANIA(TM) Coronary Stent System With Polyzene(R)-F to Treat Chronic Total Occlusion During 'Live' Case at the Paris Cardiovascular Interventions Course (Francophone) 2008

Research Shows New Class of Stent Effective in Preventing Thrombosis,

Restenosis, and Reocclusion

PARIS, Oct. 1 /PRNewswire/ -- CeloNova BioSciences, Inc., today announced that Masahiko Ochiai MD, Associate Professor, Division of Cardiology, Yokohama Hospital, Kanagawa, Japan has selected the CATANIA(TM) Coronary Stent System featuring NanoThin Polyzene(R)-F for treating a patient with a chronic total occlusion (CTO) during a live case symposium at the Paris Cardiovascular Interventions (Francophone) Congress. The CATANIA(TM) Coronary Stent System carries a CE Mark and is currently available for sale in Europe.

(Photo: )

(Logo: )

Chronic total occlusion is defined as any artery where blood flow has been completely blocked for greater than 30 days. These types of lesions are exceptionally difficult to treat with percutaneous intervention (angioplasty) because of the challenges physicians face in crossing the lesion to move the catheter into place for proper stent deployment. The CATANIA(TM) Stent was selected for this live case because Polyzene(R)-F makes it highly lubricious and delivers low restenosis rates, excellent anti-thrombosis rates, and other clinical benefits that approach or, in some cases, may exceed those of DES, while addressing some of the significant ongoing concerns with current DES technology such as product cost, risk for thrombosis, and serious challenges associated with costly long-term dual anti-platelet therapy following treatment.

"The CATANIA(TM) Stent has superb pushability, trackability, and flexibility. You can feel that the Polyzene(R)-F surface is slicker than other stents," said Thierry Corcos, MD, Service de Cardiologie, Clinique Turin, Paris, France. "For the live case, we want to really test the CATANIA(TM) Stent's capabilities in a challenging anatomy, because of the clinical evidence that Polyzene(R)-F nanocoating prevents thrombosis, restenosis and reocclusion. Based on my experience, I believe the CATANIA(TM) Stent is an ideal choice for treating coronary artery disease, including chronic total occlusions."

The rapid-exchange, cobalt-chromium CATANIA(TM) Stent features a modified open-cell design and is available in 60 sizes in lengths from 8mm to 38mm and in diameters, from 2.0 to 4.0mm. The CATANIA(TM) Stent does not contain any drugs, off-loaded materials or biological substitutes. The proprietary nanothin, highly lubricious Polyzene(R)-F is a synthesized, inorganic, biocompatible polymer that is anti-thrombotic, anti-inflammatory, bacterial-resistant, and essentially cloaks the device's presence from the body to promote healthy endothelial cell growth without stimulating platelet activation. This unique combination of stent and surface treatment effectively creates a new and different class of stent that does not require long-term dual anti-platelet therapy.

"It is exceptionally gratifying that Dr. Corcos and Dr. Ochiai selected to showcase the abilities of the CATANIA(TM) Stent in such an important, and difficult-to-treat live case, because we design all of our products from the ground up using direct feedback from the physicians who use them," said Thomas A. Gordy, President and Chief Executive Officer, CeloNova BioSciences, Inc. "We are looking forward to presenting the CATANIA(TM) long-term, First-In-Man data on the world stage later this month during the Transcatheter Therapeutics (TCT) annual meeting in Washington, DC."

For more information about CeloNova BioSciences' products and Polyzene(R)-F technology, visit .

About CeloNova BioSciences, Inc.

Headquartered in Newnan, near Atlanta, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are then enhanced by one of the Company's proprietary materials, Polyzene(R)-F. Polyzene(R)-F is highly lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant making it an ideal surface treatment for implanted medical devices. The Company's current products include its Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Other innovative devices are currently in the company's developmental pipeline. For more information, please visit .

CONTACT: Robert J. Murphy

The Storch-Murphy Group


SOURCE CeloNova BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Diageo Sponsors Medical Society of the State of New Yorks Physicians Training Program
2. Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market
3. Top Health Care Economists and Physician-Innovators Discuss Value of Medical Technology at AdvaMed 2007 Conference
4. Cynthia Haines, M.D., Named Managing Editor of Physicians Briefing News Wire
5. Young Physicians Demanding Advanced Laparoscopic Energy Instruments
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
8. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
9. Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment
10. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
11. Hot Information for Physicians Treating Vasomotor Symptoms During the Menopausal Transition
Post Your Comments:
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
(Date:6/23/2016)... 2016 adds 2016 ... its pharmaceuticals section with historic and forecast data ... more. Complete report on the Cell ... 15 companies and supported with 261 tables and ... . The Global Cell Culture Media ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
Breaking Biology News(10 mins):